Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

被引：0
|
作者：
Charles S. Fuchs
Mustafa Özgüroğlu
Yung-Jue Bang
Maria Di Bartolomeo
Mario Mandala
Min-Hee Ryu
Lorenzo Fornaro
Tomasz Olesinski
Christian Caglevic
Hyun C. Chung
Kei Muro
Eric Van Cutsem
Anneli Elme
Peter Thuss-Patience
Ian Chau
Atsushi Ohtsu
Pooja Bhagia
Anran Wang
Chie-Schin Shih
Kohei Shitara
机构：
[1] Yale Cancer Center and Smilow Cancer Hospital,Department of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Medical Faculty
[2] Istanbul University–Cerrahpaşa,Department of Internal Medicine
[3] Seoul National University College of Medicine,Department of Medical Oncology
[4] Fondazione IRCCS Istituto Nazionale Tumori,Unit of Medical Oncology
[5] University of Perugia,Department of Oncology, Asan Medical Center
[6] University of Ulsan College of Medicine,Unit of Medical Oncology, Department of Translational Research and New Technology in Medicine and Surgery
[7] Azienda Ospedaliero-Universitaria Pisana,Department of Oncological Gastroenterology
[8] Maria Skłodowska–Curie Memorial,Department of Cancer Research
[9] Instituto Oncologico Fundacion Arturo Lopez,Division of Medical Oncology, Yonsei Cancer Center
[10] Yonsei University College of Medicine,Department of Clinical Oncology
[11] Aichi Cancer Center Hospital,Department of Digestive Oncology
[12] University Hospitals Gasthuisberg Leuven and KU,Chemotherapy Centre and Oncology and Hematology Clinic
[13] The North Estonia Medical Centre,Medical Department, Division of Hematology, Oncology, and Tumor Immunology
[14] Charité–University Medicine Berlin,Department of Medicine
[15] Royal Marsden NHS Foundation Trust,Department of Gastroenterology and Gastrointestinal Oncology
[16] National Cancer Center Hospital East,Department of Medical Oncology
[17] Merck & Co.,Department of Biostatistics and Research Decision Science
[18] Inc,undefined
[19] Merck & Co.,undefined
[20] Inc,undefined
来源：
Gastric Cancer | 2022年 / 25卷
关键词：
Pembrolizumab; Chemotherapy; Gastric cancer; Gastroesophageal junction cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：197 / 206
页数：9
相关论文
共 50 条
  • [1] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    [J]. GASTRIC CANCER, 2022, 25 (01) : 197 - 206
  • [2] Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter C.
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer
    Shitara, Kohei
    Muro, Kei
    Satoh, Taroh
    Tamura, Takao
    Chin, Keisho
    Machida, Nozomu
    Hara, Hiroki
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Mayo, Carlos
    Han, Rong
    Shiratori, Shinichi
    Ohtsu, Atsushi
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 49 - 49
  • [4] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Kang, S. Peter
    Mayo, Carlos Alberto
    Ohtsu, Atsushi
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
    Shitara, Kohei
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Mayo, Carlos
    Kang, S. Peter
    Ohtsu, Atsushi
    Fuchs, Charles S.
    [J]. LANCET, 2018, 392 (10142): : 123 - 133
  • [7] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
    Wainberg, Zev A.
    Shitara, Kohei
    Van Cutsem, Eric
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol Cheol
    Lee, Jeeyun
    Castro-Salguero, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Goekkurt, Eray
    Satake, Hironaga
    Chao, Joseph
    Kher, Uma
    Shah, Sukrut
    Bhagia, Pooja
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
    Chung, Hyun Cheol
    Kang, Yoon-Koo
    Chen, Zhendong
    Bai, Yuxian
    Ishak, Wan Zamaniah Wan
    Shim, Byoung Yong
    Park, Young Lee
    Koo, Dong-Hoe
    Lu, Jianwei
    Xu, Jianming
    Chon, Hong Jae
    Bai, Li-Yuan
    Zeng, Shan
    Yuan, Ying
    Chen, Yen-Yang
    Gu, Kangsheng
    Zhong, Wen Yan
    Kuang, Shu
    Shih, Chie-Schin
    Qin, Shu-Kui
    [J]. CANCER, 2022, 128 (05) : 995 - 1003
  • [10] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC
    Ren, Shengxiang
    Feng, Jifeng
    Ma, Shenglin
    Chen, HuaJun
    Ma, Zhiyong
    Huang, Cheng
    Zhang, Li
    He, Jianxing
    Wang, Changli
    Zhou, Jianying
    Danchaivijtr, Pongwut
    Wang, Chin-Chou
    Vynnychenko, Ihor
    Wang, Kai
    Orlandi, Francisco
    Sriuranpong, Virote
    Li, Ben
    Ge, Jun
    Dang, Thao
    Zhou, Caicun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 623 - 634
12345